FoldRx Pharmaceuticals, Inc. Promising First-in-class Drug Candidate For Genetic Protein-misfolding Disease, The Scripps Research Institute Study

Published: Jul 23, 2009

Bookmark and Share

ScienceDaily (July 23, 2009) — Discoveries by Scripps Research Institute scientists have led to a promising new drug candidate—the first in its class—for patients with a genetic protein-misfolding disease. In results announced by the biopharmaceutical firm FoldRx Pharmaceuticals, Inc. July 21, 2009, the new drug tafamidis significantly halts disease progression for patients with a disease called Transthyretin (TTR) amyloid polyneuropathy (ATTR-PN).

Back to news